BRPI0804623B8 - uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos - Google Patents
uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivosInfo
- Publication number
- BRPI0804623B8 BRPI0804623B8 BRPI0804623A BRPI0804623A BRPI0804623B8 BR PI0804623 B8 BRPI0804623 B8 BR PI0804623B8 BR PI0804623 A BRPI0804623 A BR PI0804623A BR PI0804623 A BRPI0804623 A BR PI0804623A BR PI0804623 B8 BRPI0804623 B8 BR PI0804623B8
- Authority
- BR
- Brazil
- Prior art keywords
- drug
- preparation
- treatment
- patients suffering
- cognitive disorders
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 5
- 102000008100 Human Serum Albumin Human genes 0.000 title abstract 4
- 108091006905 Human Serum Albumin Proteins 0.000 title abstract 4
- 208000010877 cognitive disease Diseases 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 4
- 229940079593 drug Drugs 0.000 title abstract 4
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 238000001647 drug administration Methods 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos. a presente invenção refere-se ao uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos. a invenção é baseada no uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos, em que o modelo de administração do fármaco inclui a administração ao paciente por um mínimo de três vezes sucessivas, de uma quantidade terapeuticamente eficiente de albumina terapêutica humana por meio de troca de plasma e/ou de perfusão intravenosa, independente do conteúdo de a(beta) no sangue do paciente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200702831A ES2332846B1 (es) | 2007-10-26 | 2007-10-26 | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos. |
| ES200702831 | 2007-10-26 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0804623A2 BRPI0804623A2 (pt) | 2009-06-30 |
| BRPI0804623B1 BRPI0804623B1 (pt) | 2020-02-11 |
| BRPI0804623B8 true BRPI0804623B8 (pt) | 2021-05-25 |
Family
ID=40583637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0804623A BRPI0804623B8 (pt) | 2007-10-26 | 2008-10-23 | uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7851446B2 (pt) |
| EP (1) | EP2111868B1 (pt) |
| JP (1) | JP5437619B2 (pt) |
| CN (1) | CN101417123B (pt) |
| AR (1) | AR068901A1 (pt) |
| AU (1) | AU2008233025B8 (pt) |
| BR (1) | BRPI0804623B8 (pt) |
| CA (1) | CA2641830C (pt) |
| CL (1) | CL2008003133A1 (pt) |
| ES (2) | ES2332846B1 (pt) |
| HK (1) | HK1126689A1 (pt) |
| MX (1) | MX2008013635A (pt) |
| NZ (1) | NZ572131A (pt) |
| PL (1) | PL2111868T3 (pt) |
| PT (1) | PT2111868E (pt) |
| RU (1) | RU2414925C2 (pt) |
| UY (1) | UY31418A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10112000B2 (en) | 2010-07-08 | 2018-10-30 | Asahi Kasei Medical Co., Ltd. | Method for reducing amyloid beta concentration in blood |
| CA3033051A1 (en) * | 2016-08-18 | 2018-02-22 | Alkahest, Inc. | Blood plasma fractions as a treatment for aging-associated cognitive disorders |
| US10525107B2 (en) | 2016-08-18 | 2020-01-07 | Alkahest, Inc. | Blood plasma fractions as a treatment for aging-associated cognitive disorders |
| BR112019022402A2 (pt) * | 2017-04-26 | 2020-05-19 | Alkahest Inc | regime de dosagem para tratamento de comprometimentos cognitivo e motor com plasma sanguíneo e produtos de plasma sanguíneo |
| US11040068B2 (en) | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| MX2021000707A (es) * | 2018-07-20 | 2021-03-25 | Alkahest Inc | Regimen de dosificacion para el tratamiento de deterioros cognitivos y motores con plasma de sangre y productos de plasma de sangre. |
| EP3643319A1 (en) * | 2018-10-25 | 2020-04-29 | Grifols Worldwide Operations Limited | Use of low volume plasma exchange for the treatment of alzheimer's disease in early and middle stages |
| CA3115308A1 (en) | 2018-10-26 | 2020-04-30 | Alkahest, Inc. | Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery |
| AR125480A1 (es) * | 2021-04-30 | 2023-07-19 | Grifols Worldwide Operations Ltd | Uso de recambio plasmático terapéutico y recambio plasmático de bajo volumen para el tratamiento de un deterioro cognitivo |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3612137A1 (de) | 1986-04-10 | 1987-10-15 | Biotest Pharma Gmbh | Steriles plasmaaustauschmittel |
| US5112298A (en) | 1990-06-25 | 1992-05-12 | Baxter International Inc. | Apheresis method and device |
| US5178603A (en) | 1990-07-24 | 1993-01-12 | Baxter International, Inc. | Blood extraction and reinfusion flow control system and method |
| US6627151B1 (en) * | 1997-06-13 | 2003-09-30 | Helmut Borberg | Method for treatment diseases associated with a deterioration of the macrocirculation, microcirculation and organ perfusion |
| CA2408566A1 (en) | 2000-05-23 | 2001-11-29 | Berislav V. Zlokovic | Role of ldl receptor protein-1 (lrp-1) in alzheimer's disease |
| EP1370240A4 (en) * | 2001-03-02 | 2004-09-22 | Neuron Therapeutics Inc | NEUROPROTECTOR FORMULATIONS AND METHOD |
| AU2002366355A1 (en) | 2001-12-17 | 2003-06-30 | New York State Office Of Mental Health | SEQUESTRATION OF ABeta IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES |
| ES2440217T3 (es) | 2002-10-04 | 2014-01-28 | Prana Biotechnology Limited | Compuestos neurológicamente activos |
| AU2003303198A1 (en) | 2002-12-19 | 2004-07-14 | New York University | Method for treating amyloid disease |
| DE502004003834D1 (de) | 2003-02-13 | 2007-06-28 | Octapharma Ag | Verfahren zur herstellung einer albuminlösung |
| AU2004311577A1 (en) | 2003-07-11 | 2005-07-21 | Myriad Genetics, Inc. | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease |
| AT413336B (de) * | 2003-09-12 | 2006-02-15 | Mattner Frank Dr | Apherese-vorrichtung |
| US20050182044A1 (en) | 2004-02-17 | 2005-08-18 | Bruinsma Gosse B. | Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate |
| AT500483B1 (de) | 2004-07-13 | 2006-01-15 | Mattner Frank Dr | Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung |
| US7436304B1 (en) | 2005-07-19 | 2008-10-14 | Visible Assets, Inc | Evidence tracking |
-
2007
- 2007-10-26 ES ES200702831A patent/ES2332846B1/es not_active Expired - Fee Related
-
2008
- 2008-10-17 RU RU2008141076/15A patent/RU2414925C2/ru active
- 2008-10-17 AR ARP080104523A patent/AR068901A1/es unknown
- 2008-10-17 NZ NZ572131A patent/NZ572131A/en unknown
- 2008-10-22 PT PT83803015T patent/PT2111868E/pt unknown
- 2008-10-22 EP EP08380301.5A patent/EP2111868B1/en active Active
- 2008-10-22 PL PL08380301T patent/PL2111868T3/pl unknown
- 2008-10-22 ES ES08380301T patent/ES2428698T3/es active Active
- 2008-10-23 BR BRPI0804623A patent/BRPI0804623B8/pt active IP Right Grant
- 2008-10-23 CL CL2008003133A patent/CL2008003133A1/es unknown
- 2008-10-23 MX MX2008013635A patent/MX2008013635A/es active IP Right Grant
- 2008-10-23 UY UY31418A patent/UY31418A1/es not_active Application Discontinuation
- 2008-10-23 CN CN2008101705786A patent/CN101417123B/zh active Active
- 2008-10-24 JP JP2008274076A patent/JP5437619B2/ja active Active
- 2008-10-24 AU AU2008233025A patent/AU2008233025B8/en active Active
- 2008-10-24 US US12/257,814 patent/US7851446B2/en active Active
- 2008-10-24 CA CA2641830A patent/CA2641830C/en active Active
-
2009
- 2009-07-02 HK HK09105923.2A patent/HK1126689A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT2111868E (pt) | 2013-10-17 |
| PL2111868T3 (pl) | 2014-01-31 |
| RU2414925C2 (ru) | 2011-03-27 |
| EP2111868A1 (en) | 2009-10-28 |
| HK1126689A1 (en) | 2009-09-11 |
| CN101417123A (zh) | 2009-04-29 |
| ES2428698T3 (es) | 2013-11-08 |
| ES2332846B1 (es) | 2010-07-08 |
| AU2008233025B8 (en) | 2013-07-25 |
| CN101417123B (zh) | 2012-06-27 |
| BRPI0804623B1 (pt) | 2020-02-11 |
| UY31418A1 (es) | 2009-05-29 |
| JP5437619B2 (ja) | 2014-03-12 |
| AU2008233025A1 (en) | 2009-05-14 |
| BRPI0804623A2 (pt) | 2009-06-30 |
| AR068901A1 (es) | 2009-12-16 |
| AU2008233025B2 (en) | 2013-06-27 |
| CA2641830C (en) | 2013-07-16 |
| NZ572131A (en) | 2010-06-25 |
| CA2641830A1 (en) | 2009-04-26 |
| EP2111868B1 (en) | 2013-08-21 |
| JP2009108059A (ja) | 2009-05-21 |
| RU2008141076A (ru) | 2010-04-27 |
| US20090111740A1 (en) | 2009-04-30 |
| ES2332846A1 (es) | 2010-02-12 |
| CL2008003133A1 (es) | 2009-08-07 |
| US7851446B2 (en) | 2010-12-14 |
| MX2008013635A (es) | 2009-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0804623B8 (pt) | uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos | |
| American Society of Anesthesiologists Task Force on Chronic Pain Management | Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine | |
| Farrero et al. | Survival in amyotrophic lateral sclerosis with home mechanical ventilation: the impact of systematic respiratory assessment and bulbar involvement | |
| Brill | How to avoid interface problems in acute noninvasive ventilation | |
| JP2022009125A5 (pt) | ||
| TR200001891T2 (tr) | ASPB28- İnsan ensülini ve kullanımı. | |
| BRPI0513200A (pt) | uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas | |
| Hallonsten et al. | EAPD guidelines on sedation in paediatric dentistry | |
| WO2008022189A3 (en) | Administration of high potency platinum compound formulations by inhalation | |
| EP2216024A3 (en) | Use of Ranolazine for the treatment of cardiovascular diseases | |
| Chen et al. | Efficacy and safety of dexmedetomidine versus propofol for the sedation of tube-retention after oral maxillofacial surgery | |
| JP2010518164A5 (pt) | ||
| WO2019098621A1 (ko) | 립실 테이프 | |
| Freye et al. | Fentanyl in the fourth cerebral ventricle causes respiratory depression in the anesthetized but not in the awake dog | |
| BR112014004339A2 (pt) | suspensão oral | |
| Salinas Salmeron et al. | Effects site concentrations of propofol using target-controlled infusion in dental treatment under deep sedation among different intellectual disability types | |
| Cangemi Jr | Administration of general anesthesia for outpatient orthognathic surgical procedures | |
| Lu et al. | Nursery education for diabetes | |
| CN114588164A (zh) | 瑞马唑仑在预防围术期低体温和寒战中的应用 | |
| CN100551381C (zh) | 一种治疗婴幼儿毛细支气管炎的中药药剂 | |
| CN202234376U (zh) | 一种预防保健中药药枕 | |
| Ohshita et al. | Anesthetic management of a patient with multiple sclerosis | |
| Giuliani | A severe delayed infusion reaction induced by trastuzumab: a life-threatening condition | |
| Doghramji et al. | Pitolisant in combination with other medications for the management of narcolepsy | |
| CN201958403U (zh) | 一种药枕 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B03A | Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: GRIFOLS, S.A. (ES) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/02/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |